Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
Open accessThe DOI matches its Crossref record.
Abstract
Bosutinib is an Src/Abl tyrosine kinase inhibitor (TKI) indicated for adults with Ph+ chronic myeloid leukemia (CML) resistant/intolerant to prior TKIs. This long‐term update of an ongoing phase 1/2 study evaluated the efficacy and safety of third‐/fourth‐line bosutinib in adults with chronic phase (CP) CML. Median durations of treatment and follow‐up were 8.6 (range, 0.2–87.7) months and 32.7 (0.3–93.3) months, respectively. Cumulative confirmed complete hematologic response (cCHR) and major cytogenetic response (MCyR) rates were 74% (95% CI, 65–81%) and 40% (31–50%), respectively; Kaplan–Meier (K–M) probability of maintaining cCHR or MCyR at 4 years was 63% (95% CI, 50–73%) and 69% (52–81%). Cumulative incidence of on‐treatment disease progression (PD)/death at 4 years was 24% (95% CI, 17–33%); K–M 4‐year overall survival was 78% (68–85%). Baseline Ph+ cells ≤35 vs. ≥95% was prognostic of MCyR and CCyR by 3 and 6 months, increased baseline basophils was prognostic of PD/death, and no prior response to second‐line TKI was prognostic of death. Common adverse events included diarrhea (83%), nausea (48%), vomiting (38%), and thrombocytopenia (39%). Bosutinib demonstrates durable efficacy and a toxicity profile similar to previous bosutinib studies in CP CML patients resistant/intolerant to multiple TKIs, representing an important treatment option for patients in this setting. This trial is registered at www.clinicaltrials.gov (NCT00261846). Am. J. Hematol. 91:1206–1214, 2016. © 2017 The Authors American Journal of Hematology Published by Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cortes, J. E., Gambacorti-Passerini, C., Deininger, M. W., Mauro, M. J., Chuah, C., Kim, D.-W., Dyagil, I., Glushko, N., Milojkovic, D., le Coutre, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7162 · Cited by 495
Self-citationZhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hochhaus, A., Saussele, S., Rosti, G., Mahon, F.-X., Janssen, J. J. W. M., Hjorth-Hansen, H., Richter, J., & Buske, C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx219 · Cited by 343
Réa, D., Mauro, M. J., Boquimpani, C., Minami, Y., Lomaia, E., Voloshin, S., Turkina, A., Kim, D.-W., Apperley, J. F., Abdo, A., et al. (2021) · Blood · doi:10.1182/blood.2020009984 · Cited by 342
Self-citationChronic myeloid leukemia, version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., Curtin, P., DeAngelo, D. J., Gotlib, J., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0071 · Cited by 277
Self-citation
Metadata
- Authors
- Cortes, J. E., Khoury, H. J., Kantarjian, H. M., Lipton, J. H., Kim, D., Schafhausen, P., Matczak, E., Leip, E., Noonan, K., Brümmendorf, T. H., & Gambacorti‐Passerini, C.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2016-09-15
- Volume
- 91
- Issue
- 12
- Pages
- 1206-1214
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2516537857
- Cited by
- 114
- References
- 0
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. https://app.cochat.ai/papers/10.1002/ajh.24536
- The paper
- Cortes, J. E., Khoury, H. J., Kantarjian, H. M., Lipton, J. H., Kim, D., Schafhausen, P., Matczak, E., Leip, E., Noonan, K., Brümmendorf, T. H., & Gambacorti‐Passerini, C. (2016). Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. American Journal of Hematology. https://doi.org/10.1002/ajh.24536
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.